000 | 01992 a2200601 4500 | ||
---|---|---|---|
005 | 20250516025811.0 | ||
264 | 0 | _c20111122 | |
008 | 201111s 0 0 eng d | ||
022 | _a1520-6017 | ||
024 | 7 |
_a10.1002/jps.22534 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aWang, Xianhuo | |
245 | 0 | 0 |
_aPreparation, characterization, pharmacokinetics, and bioactivity of honokiol-in-hydroxypropyl-β-cyclodextrin-in-liposome. _h[electronic resource] |
260 |
_bJournal of pharmaceutical sciences _cAug 2011 |
||
300 |
_a3357-3364 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _a2-Hydroxypropyl-beta-cyclodextrin |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xchemistry |
650 | 0 | 4 |
_aBiphenyl Compounds _xchemistry |
650 | 0 | 4 |
_aCell Survival _xdrug effects |
650 | 0 | 4 | _aChemistry, Pharmaceutical |
650 | 0 | 4 | _aChromatography, High Pressure Liquid |
650 | 0 | 4 | _aCrystallization |
650 | 0 | 4 |
_aDrug Carriers _xchemistry |
650 | 0 | 4 |
_aDrug Compounding _xinstrumentation |
650 | 0 | 4 | _aDrug Stability |
650 | 0 | 4 | _aHep G2 Cells |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aInjections, Intravenous |
650 | 0 | 4 |
_aLignans _xchemistry |
650 | 0 | 4 | _aLiposomes |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMicroscopy, Electron, Transmission |
650 | 0 | 4 | _aParticle Size |
650 | 0 | 4 | _aRats |
650 | 0 | 4 | _aRats, Sprague-Dawley |
650 | 0 | 4 | _aSolubility |
650 | 0 | 4 | _aSurface Properties |
650 | 0 | 4 | _aX-Ray Diffraction |
650 | 0 | 4 |
_abeta-Cyclodextrins _xchemistry |
700 | 1 | _aDeng, Linyu | |
700 | 1 | _aCai, Lulu | |
700 | 1 | _aZhang, Xiaoyan | |
700 | 1 | _aZheng, Hao | |
700 | 1 | _aDeng, Chongyang | |
700 | 1 | _aDuan, Xingmei | |
700 | 1 | _aZhao, Xia | |
700 | 1 | _aWei, Yuquan | |
700 | 1 | _aChen, Lijuan | |
773 | 0 |
_tJournal of pharmaceutical sciences _gvol. 100 _gno. 8 _gp. 3357-3364 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1002/jps.22534 _zAvailable from publisher's website |
999 |
_c20659710 _d20659710 |